FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to a method for the treatment of cancer or a proliferative disease in a subject. The method for the treatment of cancer or a proliferative disease in a subject includes administration to the subject of negatively charged particles containing copolymer of lactic and glycolic acids (PLGA) by means of intravenous injection and administration of a modulator of control points of an immune response by means of intravenous injection. In this case, negatively charged particles do not contain attached peptide, antigen fragments, or other bioactive substances. Negatively charged particles are characterized by a zeta-potential from -80 to -30 mV, and negatively charged particles are injected at a dose from 0.1 to 10 mg/kg. At the same time, the modulator of control points of an immune response is an antibody targeting programmed cell death protein-1 (PD1), programmed cell death protein ligand-1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
EFFECT: above-described method allows for efficient treatment of cancer or proliferative diseases in a subject.
22 cl, 4 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| TREATING LUNG CANCER BY COMBINATION OF ANTI-PD-1 AND OTHER ANTI-CANCER AGENTS | 2015 |
|
RU2695332C2 |
| USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | 2018 |
|
RU2780354C2 |
| PD1-4-1BBL FUSION PROTEIN AND METHODS OF ITS USE | 2018 |
|
RU2769513C2 |
| COMBINED THERAPY FOR TREATING CANCER USING A RECOMBINANT POXVIRUS EXPRESSING A TUMOR ANTIGEN AND AN ANTAGONIST OR AGONIST OF AN IMMUNE CONTROL POINT MOLECULE | 2015 |
|
RU2724433C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| COMBINED DRUGS FOR TREATMENT OF CANCER OR INFECTION | 2016 |
|
RU2777945C2 |
| METHODS AND COMPOSITIONS FOR TREATING TUMORS | 2017 |
|
RU2741786C2 |
| PD-1 ANTIBODIES AND USE THEREOF | 2016 |
|
RU2722451C1 |
